Cellectis (NASDAQ:CLLS) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Cellectis (NASDAQ:CLLS) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.08, Zacks reports. Cellectis had a negative net margin of 84.92% and a negative return on equity of 69.38%.

Cellectis Stock Up 3.4%

Shares of NASDAQ:CLLS traded up $0.13 during trading hours on Monday, reaching $3.98. The stock had a trading volume of 29,003 shares, compared to its average volume of 41,561. Cellectis has a 1 year low of $1.33 and a 1 year high of $5.48. The firm’s 50 day moving average is $3.68 and its 200-day moving average is $4.00. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.62 and a current ratio of 1.62. The stock has a market capitalization of $399.35 million, a price-to-earnings ratio of -5.94 and a beta of 2.94.

Institutional Investors Weigh In On Cellectis

A number of large investors have recently modified their holdings of CLLS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Cellectis by 228.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock valued at $5,856,000 after purchasing an additional 3,284,409 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Cellectis in the 4th quarter valued at $15,385,000. Citadel Advisors LLC purchased a new position in shares of Cellectis in the 3rd quarter valued at $633,000. Marshall Wace LLP grew its position in shares of Cellectis by 1,610.3% in the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after buying an additional 168,038 shares during the last quarter. Finally, Acadian Asset Management LLC grew its position in shares of Cellectis by 132.9% in the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 26,461 shares during the last quarter. 63.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on CLLS shares. Jefferies Financial Group began coverage on shares of Cellectis in a report on Tuesday, February 17th. They issued a “buy” rating and a $7.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a report on Monday, April 20th. Finally, Citizens Jmp reiterated a “market outperform” rating and set a $8.00 target price on shares of Cellectis in a report on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $6.75.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.